|
|
Pulmonary Medicine
Research
The Pulmonary Medicine faculty participates in basic and clinical research, examining the causes and treatments of a wide range of pediatric pulmonary disorders.
Dr. Steven Abman's pioneering work in the use of nitric oxide to treat infants and children with pulmonary hypertension resulted in his receiving the prestigious Excellence in Pediatric Research Award from the American Academy of Pediatrics.
Dr. Frank Accurso is internationally known for his work with newborn screening and the description of early lung disease in infants with cystic fibrosis. He has been acclaimed as one of the top clinical researchers and care providers by the Cystic Fibrosis Foundation. Following the selection of the University of Colorado as one of the Cystic Fibrosis Foundation's Therapeutics Development Centers, he has been increasingly active in the development and study of new therapies and techniques for outcomes research.
Dr. Vivek Balasubramaniam's research interest is in the mechanisms underlying lung vascular and alveolar development, especially in response to stress and injury. His focus is on the role of nitric oxide in the growth and development of blood vessels in the lung.
Dr. Keith Cavanaugh's research activities include working with the State of Colorado in the ongoing development of a program that will help health care providers address the risks of Second Hand Smoke Exposure (SHS) with their patients and motivate caregivers to decrease tobacco exposure to their children.
Dr. Robin Deterding is nationally recognized for her research in children with interstitial lung disease (chILD), clinical studies in cystic fibrosis and medical education. Her current clinical research focus includes interstitial lung disease, complex lung disease and pulmonary complications of bone marrow transplant and connective tissue disease in children. She is a founding member of the Children's Interstitial Lung Disease (chILD) Foundation.
Dr. Mark Duncan has developed and applied the tools of proteomics to a wide array of clinical problems for over a decade. Current research projects include studies of cystic fibrosis, endocrine function and several cancers including those of the thyroid, prostate, breast, cervix and lung. Dr. Duncan's work is highly collaborative and diverse in nature.
Dr. Monica Federico is developing an outpatient asthma program to complement the inpatient asthma pathway at The Children's Hospital. She is working on several clinical studies involving outcomes research in asthma. Dr. Federico is also involved in the care of Spanish-speaking children with pulmonary disease, including asthma and cystic fibrosis.
Dr. Stephen Hunsucker is interested in using proteomics as a tool for translational research. He is actively involved in the discovery and validation of biomarkers that have clinical utility in the management and treatment of pediatric diseases. He is currently pursuing validation of a panel of putative biomarkers that are believed to be indicative of pulmonary exacerbation and predictive of lung function decline in cystic fibrosis.
Dr. Gwendolyn Kerby has developed the infant pulmonary function testing laboratory and is active in several clinical studies involving young children with cystic fibrosis, asthma bronchopulmonary dysplasia and pulmonary hypertension. She is the Director of the Asthma Management Program and has developed an asthma pathway for The Children's Hospital inpatient service.
Dr. Gary Larsen, based at the National Jewish Medical and Research Center, is internationally recognized for his research into the basic causes of asthma. Additionally, he is currently involved as one of the directors of several multicenter national studies looking at therapeutic options for children with asthma. He has participated in several NIH study groups and remains actively involved with setting national goals for asthma research.
Dr. Scott Sagel is nationally recognized for his clinical research involving children with cystic fibrosis. He is currently funded by the National Institutes of Health and the Cystic Fibrosis Foundation to study biomarkers of airway inflammation in children with cystic fibrosis. He was recently selected to chair the Induced Sputum Committee for the Cystic Fibrosis Foundation's Therapeutics Development Network.
Dr. Jeffrey Wagener is actively involved with epidemiologic and clinical research in cystic fibrosis. He helped develop the use of flexible bronchoscopy for evaluating the extent of airway inflammation in infants with cystic fibrosis and is currently involved with numerous studies conducted by the Cystic Fibrosis Foundation's Therapeutics Development Network. As an advisor for the Epidemiologic Study for Cystic Fibrosis, he is involved with many projects identifying associations between treatments and outcomes in cystic fibrosis.
Dr. Carl White, also based at the National Jewish Medical and Research Center, is a world leader in the study of oxidant-mediated lung injury in humans. Having developed several animal and cell culture models for lung injury, he has extended his studies from "the bench to the bedside" by looking at how cells are injured by oxidants and the preventive benefit of antioxidants and other protective interventions.
|
|
